Beverly, Mass.—— Enzymatics, Inc., a rapidly growing provider of molecular biology reagents, today announced that patent infringement claims filed against the company by New England BioLabs (NEB) have been significantly narrowed. NEB has completely withdrawn the claim that Enzymatics infringed on U.S. Patent No. 5,670,637 (‘637) and has conceded that U.S. Patent No. 5,874,557 (‘557) has expired, withdrawing its request for injunctive relief.

“Enzymatics continues to steadfastly defend against the remaining baseless infringement allegations,” said Jon DiVincenzo, Enzymatics’ President and Chief Executive Officer. In November 2012, NEB filed its original complaint in the U.S. District Court for the District of Massachusetts (Civil Action No. 1:12-cv-12125) alleging that an Enzymatics product infringed on ‘637 and ‘557 and sought damages and an injunction preventing future sales of the product. Enzymatics asserted a counterclaim accusing NEB of abusing legal process by knowingly asserting frivolous claims solely for the purpose of harassment and harming its business.

“Enzymatics will vigorously pursue our counterclaims against NEB,” continued Mr. DiVincenzo. “Despite these distractions, Enzymatics continues to consistently deliver the highest quality and value enzymes to drive the successes of our customers in the rapidly expanding genomic sciences community.” Mr. DiVincenzo joined Enzymatics in 2012. He was previously President of Millipore Corporation’s Bioscience Business Unit.

About Enzymatics

Enzymatics is a class-leading, ISO 13485-certified manufacturer of reagents and kits for life science and

diagnostic applications. Renowned for quality, responsiveness, and flexibility, we focus on the

commercial success of our partners. For more information please visit www.enzymatics.com.